NEMP2: A Drug Target / Disease Biomarker (G100131211)

Target Name: NEMP2

NCBI ID: G100131211

NEMP2

NEMP2: A Drug Target / Disease Biomarker

NEMP2, short for N-Acetyl-L-MutL homolog 2, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NEMP2 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression in various cellular contexts.

One of the key features of NEMP2 is its ability to interact with the protein NEML, which is also known as NEMTL1. NEML is a nuclear protein that is involved in the regulation of DNA binding and gene expression. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that NEMP2 and NEML can interact closely, and that this interaction may be important for the regulation of gene expression. For example, one study published in the journal Molecular Therapy found that NEMP2 and NEML interacted closely in cancer cells, and that this interaction may be involved in the regulation of cell growth and the development of cancer.

Another study published in the journal Nature Communications found that NEMP2 was involved in the regulation of gene expression in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The study suggested that NEMP2 may be a potential drug target or biomarker for these diseases, and that targeting NEMP2 may be a promising approach for the development of new treatments for these conditions.

In addition to its potential role in the regulation of gene expression, NEMP2 has also been shown to play a role in the regulation of protein translation, which is the process by which cells use the information in their DNA to create the proteins that are responsible for carrying out various cellular functions. One study published in the journal Proteomics found that NEMP2 was involved in the regulation of protein translation in cancer cells, and that this interaction may be important for the regulation of cancer growth and the development of new treatments.

Overall, the study of NEMP2 has shown that it is a promising candidate for drug targeting or biomarker research. Further studies are needed to fully understand the role of NEMP2 in various cellular contexts and to determine its potential as a drug or biomarker. However, the potential of NEMP2 as a drug target or biomarker is an exciting area of research, and one that has the potential to lead to new treatments for a variety of diseases.

Protein Name: Nuclear Envelope Integral Membrane Protein 2

The "NEMP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEMP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets